What Doxoril-M Treats: Main Uses and Benefits

The medication is commonly used when symptoms intensify and supportive relief is needed. It assists patients during phases of increased distress or discomfort and supports the easing of symptoms that create noticeable physiological strain, which may help with assistance in symptom stabilization. Doxoril-M is considered relevant in conditions involving episodic or fluctuating manifestations and provides supportive relief when symptoms interfere with routine activities.

This combination is applied in contexts involving inflammatory or irritative processes and helps address symptom clusters that may become disruptive. It is generally indicated for conditions like asthma and the relief of symptoms of allergic rhinitis, including the acute prevention of exercise-induced bronchoconstriction (EIB). The overall therapeutic support is applied in addressing symptoms such as wheezing, shortness of breath, and chest tightness.

“It provides supportive relief that helps patients cope more steadily with difficult episodes and assists with maintaining functional stability.”

Quick Fact: Helps manage Wheezing and Chest Tightness

Who can and cannot use Doxoril-M?

The eligibility for Doxoril-M, a combination of doxofylline and montelukast, is strictly defined by regulatory documents, which outline mandatory contraindications and populations requiring special medical consideration.

---

Contraindicated Populations (Must Not Use)

Official labeling strictly prohibits the use of Doxoril-M in patients with:

• Hypersensitivity or Allergy: Individuals with a known allergy to doxofylline, montelukast, or any similar xanthine derivative (such as aminophylline).
• Severe Cardiovascular Conditions: Patients experiencing acute myocardial infarction (heart attack), severe hypotension (low blood pressure), or other serious heart problems.
• Lactation: Use is not recommended or contraindicated in women who are breastfeeding.
• Acute Asthma Attack: This medicine is for control and prevention, and must not be used for immediate relief during a sudden, acute asthma attack.

---

Restrictions and Special Consideration

Use is generally restricted or requires close medical supervision in the following groups:

Population / Condition	Eligibility Status
Children & Adolescents	Not recommended for those under 15 years of age, as safety is not adequately established.
Pregnancy	Use is generally advised against or permitted only when benefits clearly outweigh risks, as per medical discretion.
Liver or Kidney Impairment	Requires caution and close monitoring; dosage adjustment may be necessary in severe cases.
Other Conditions	Caution is mandatory for patients with peptic ulcer, hypertension (high blood pressure), hyperthyroidism (overactive thyroid), or existing concomitant infections.

Interactions with other medicines and products

This section details the officially documented interaction patterns for Doxoril-M, which combines Doxofylline and Montelukast, based strictly on government regulatory sources.

---

Contraindicated and Exposure-Altering Combinations

Co-administration with other xanthine derivatives (such as Theophylline) and Ephedrine is formally classified as contraindicated due to the risk of additive effects and toxic synergism.

Interactions that modify the clearance of the active ingredients are officially documented:

• Doxofylline Exposure: Macrolide antibiotics (e.g., Erythromycin) and H2 receptor antagonists (e.g., Cimetidine) may decrease the hepatic clearance of Doxofylline, leading to elevated systemic blood concentrations. Conversely, agents like Phenytoin may increase clearance.
• Montelukast Exposure: The inhibitor Gemfibrozil significantly increases Montelukast systemic exposure (AUC) by approximately 4.4-fold, although routine dosage adjustment is not always required per the regulatory label. Rifampicin can officially decrease Montelukast plasma concentration.

Pharmacodynamic and Substance Restrictions

Official documents advise specific constraints:

• Caffeine: Doxofylline should not be administered together with caffeine-containing beverages and foods.
• Other Drugs: The regulatory profile for Montelukast found no clinically important effects on the pharmacokinetics of co-administered medicines like Warfarin or Oral Contraceptives.
• Population Note: The half-life of Doxofylline may be prolonged in patients with Congestive Heart Failure or Liver Disease, potentially heightening the effects of exposure-increasing interactions.

Doxoril-M is a fixed-dose combination drug whose components act via distinct, yet complementary, mechanistic domains to modulate pathways associated with heightened physiological responses in the respiratory system. The combined effect involves the simultaneous modulation of two distinct signaling cascades, resulting in altered physiological responsiveness within targeted systems.

---

Modulation of Smooth Muscle Relaxation Signaling

This domain involves the action of the Doxofylline component, which alters smooth muscle signaling via inhibition of phosphodiesterase. It engages mechanisms that inhibit phosphodiesterase (PDE) enzymes, leading to an increase in the intracellular second messenger, cyclic adenosine monophosphate (cAMP), within smooth muscle cells. The key pathway effect is the promotion of altered conformational changes in smooth muscle proteins, which results in altered lumen diameter.

---

Antagonism of Inflammatory Mediator Pathways

This domain is addressed by the Montelukast component, which is a leukotriene receptor antagonist. It engages mechanisms by selectively blocking the CysLT1 receptor, thereby interfering with the binding and subsequent actions of leukotrienes. This action suppresses the signaling cascade initiated by leukotrienes, thereby influencing processes that mediate airway hyperresponsiveness and mucosal fluid accumulation.

How Doxoril-M is used: Administration Guidelines

This section describes the instructions for the use of Doxoril-M, a fixed-dose combination medicine.

---

Dosing and Administration

Doxoril-M is an oral medicine formulated as a tablet or film-coated tablet and must be swallowed whole; the tablet should not be broken, chewed, or crushed. The standard regimen is one tablet once daily, typically combining 400 mg Doxofylline with 10 mg Montelukast, though regional prescribing may include higher sustained-release strengths.

---

Timing and Schedule

For consistent long-term use, the daily dose is generally recommended to be taken in the evening to align with the established administration schedule for the Montelukast component when used for chronic respiratory issues. The tablet may be administered with or without food.

This medicine is intended strictly for long-term maintenance and should not be used for acute respiratory distress or sudden breathing problems. Treatment must be continued daily, even during periods of stable breathing function.

---

Procedural Rules

• Missed Dose: If a dose is missed, it is recommended to skip the missed dose and take the next tablet at the regularly scheduled time; do not double the dose to compensate.
• Age and Adjustments: The 10 mg Montelukast strength is indicated for patients 15 years of age and older. No specific dosage adjustment is required for older adults or patients with mild to moderate kidney (renal) or liver (hepatic) impairment.

Research Evidence / Overview of Studies

Key Findings on Efficacy

Clinical trials have evaluated Doxoril-M, a combination of Doxofylline and Montelukast, to investigate its role in managing chronic respiratory conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD).

Research studies measured changes in Forced Expiratory Volume in 1 second (FEV1), a key lung function metric. Pooled data analyses have documented a change in the frequency of asthma events and a reduction in the use of rescue medications compared to placebo in trial participants. Doxofylline alone has been measured in long-term trials lasting up to one year, which tracked changes in lung function and the incidence of asthma events.

---

Safety and Side Effects Data

Research included long-term investigation of the Doxofylline component. Safety data on serious adverse events were collected from research participants, where data on non-serious events were noted in the majority of reports. Common non-serious events analyzed in clinical research included headache, nausea, insomnia, and vomiting.

---

Combination Therapy Findings

Studies examined the two components of Doxoril-M, Doxofylline and Montelukast, often in combination with inhaled corticosteroids (like Budesonide). Participants receiving combination regimens in clinical trials measured changes in patient-reported metrics, such as symptom scores and quality of life. The evidence explored whether adding Doxofylline to standard therapy could provide an added benefit in lung function metrics compared to other combinations.

Key Studies & References

1. Efficacy and safety profile of doxofylline in asthma: a meta-analysis
2. ISRCTN10030693: Assessing the long-term efficacy and safety of doxofylline in treating asthma (The LESDA study)

Common questions about Doxoril-M (FAQ)

Q: Is Doxoril-M a type of antibiotic?

Doxoril-M is a fixed-dose combination medicine. It is classified by regulatory bodies as a bronchodilator, which is a type of methylxanthine derivative, and a leukotriene receptor antagonist (LTRA). It is not defined as an antibiotic.

Q: Is it okay to drink coffee or tea while using Doxoril-M?

Official product information advises that the Doxofylline component of the medicine should not be administered together with caffeine-containing beverages and foods. Coffee and tea are restricted because they contain caffeine.

Q: What kind of foods are officially known to interact with Doxoril-M?

The primary official restriction is to avoid caffeine-containing beverages and foods due to potential interaction with Doxofylline. Additionally, research suggests that the systemic exposure of the Montelukast component may be increased when it is taken with grapefruit juice.

Q: Is there any information about Doxoril-M use during pregnancy?

Official documentation states that use during pregnancy is generally advised against or permitted only when the benefits clearly outweigh the risks. This assessment is made by a healthcare provider based on the balance of risks and benefits.

Q: Is Doxoril-M the same as Doxoril?

Doxoril-M is a fixed-dose combination medicine containing two active ingredients: Doxofylline and Montelukast. The name Doxoril typically refers to the single agent, Doxofylline, without the Montelukast component.

Q: Why are there different versions of Doxoril-M mentioned online?

Official product documents describe different fixed-dose formulations of the medicine. These versions may vary in the strength of the Doxofylline component, such as sustained-release (SR) strengths of 400 mg or 800 mg, which are co-formulated with Montelukast 10 mg.

Q: Can Doxoril-M affect sleep patterns?

Yes, regulatory information for the Montelukast component lists sleep disorders—including insomnia and nightmares—as documented adverse reactions. Other neuropsychiatric events have also been reported.

Q: Can Doxoril-M be taken on an empty stomach?

Official administration guidelines state that the tablet may be administered with or without food.

Q: Why is Doxoril-M prescribed over other options?

The combination is recognized for providing a dual action principle, simultaneously offering both bronchodilation and anti-inflammatory effects. The Doxofylline component is also noted in pharmacological studies for having a distinct and improved tolerability profile compared to older compounds in its class.

Q: Do studies suggest Doxoril-M has a consistent effect across different age groups?

Regulatory data indicates that the way the body processes the Montelukast component (pharmacokinetics) is similar in adolescents (age 15 and older) and young adults. Furthermore, routine dosage adjustment is not specifically required for older adults.

Q: Can someone who is breastfeeding use Doxoril-M?

Official labeling strictly contraindicates or does not recommend the use of this medicine in women who are breastfeeding (during lactation).

Q: How quickly can a person expect Doxoril-M to start working?

The Montelukast component is rapidly absorbed, reaching peak concentrations in about 3 to 4 hours. Studies suggest that the effect on asthma control parameters may occur relatively quickly after the rapid absorption of the Montelukast component.

Q: Is Doxoril-M safe to use if someone has heart problems?

Official regulatory documents list severe cardiovascular conditions, such as acute myocardial infarction (heart attack) and severe hypotension (low blood pressure), as strict contraindications. Caution and monitoring are specified in regulatory documents for patients with conditions such as Congestive Heart Failure.

Q: Is Doxoril-M a controlled substance?

Regulatory documentation confirms that Doxoril-M is a prescription-only medicine and requires a healthcare provider's authorization to be dispensed. The medicine is not typically scheduled as a controlled substance.

Q: Does Doxoril-M affect blood sugar levels?

Regulatory research on the Montelukast component indicated that the medicine did not alter the degree of hyperglycemia (high blood sugar) compared to diabetic controls in animal models.

Q: What should be done if a user suspects a severe reaction to Doxoril-M?

Regulatory bodies advise patients and caregivers to be alert to serious risks, such as neuropsychiatric events. Patients are informed they should contact a healthcare professional immediately if any adverse reactions occur, and they are encouraged to report suspected reactions to their national regulatory scheme.

Q: How long does Doxoril-M stay in the body after the last dose?

The length of time the medicine remains in the body is based on the half-life of its components. The half-life of Doxofylline is stated to be about 6 to 8 hours, while the mean half-life of Montelukast is around 2.7 to 5.5 hours.

Q: Is Doxoril-M a non-steroidal anti-inflammatory drug (NSAID)?

No. Doxoril-M is classified as a combination medicine containing a bronchodilator and a leukotriene receptor antagonist (LTRA). It is not part of the non-steroidal anti-inflammatory drug (NSAID) class.

Q: What kind of monitoring is typically required while using Doxoril-M?

Regulatory information states that routine blood level checking for the Doxofylline component is generally not essential at the standard recommended dose. However, close monitoring and caution are specified for patients with severe liver or kidney impairment.

Q: Does Doxoril-M affect the liver?

Official documents list elevated liver enzymes as a common side effect of the medicine. Caution and close monitoring are specifically specified for patients with pre-existing liver impairment.

Q: Are there any known interactions with grapefruit or grapefruit juice?

Regulatory-supporting research suggests that the plasma concentration of the Montelukast component may be higher when it is administered with grapefruit juice. This is due to grapefruit's potential effects on drug metabolism.

Q: What is the source of the active ingredient in Doxoril-M?

Both active ingredients within Doxoril-M, Doxofylline and Montelukast, are classified as synthetic compounds that are manufactured rather than being derived from natural sources.

Q: Is Doxoril-M a brand name or a generic name?

Doxoril-M is a brand name for the fixed co-formulation of Doxofylline and Montelukast. Doxofylline is the generic name of one of the active components and is available worldwide under numerous different brand names.

Q: Are there official warnings about operating machinery while using Doxoril-M?

Official warnings are provided because the medicine may cause documented side effects such as dizziness or tiredness/drowsiness. Official safety recommendations exist for individuals experiencing these effects, which often include caution regarding driving or operating heavy machinery.

Q: Does Doxoril-M affect blood pressure?

Official documents note that the medicine is strictly contraindicated in patients with severe hypotension (low blood pressure). Caution is also mandatory for patients diagnosed with existing hypertension (high blood pressure).

How to Store and Dispose of Doxoril-M

Doxoril-M (Doxofylline/Montelukast) must be stored and disposed of according to specific regulatory requirements to maintain its stability and ensure public safety.

Official Storage Conditions

The medication must be kept in a cool and dry place at temperatures not exceeding 30 C. The tablets must be protected from light and moisture and stored in their original container, which should be kept tightly closed.

Safety and Disposal

For safety, Doxoril-M must be stored out of the sight and reach of children and pets at all times. Unused or expired medication must be disposed of safely by following the instructions mentioned on the package label or by utilizing an approved pharmaceutical take-back program, adhering to local regulations for medicinal waste.